Medical News

RSS

3M to acquire Arizant for $810M

3M announced today it has entered into a definitive agreement to acquire Arizant Inc. for a purchase price of $810 million in cash. Based in Eden Prairie, Minn., Arizant is a leading manufacturer of patient warming solutions designed to prevent hypothermia in surgical settings.

9 Sep 2010

Caliper launches toolkit for direct co-registration of images from multiple preclinical imaging modalities

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today introduced software and accessory items to enable the direct co-registration of images from multiple preclinical imaging modalities.

9 Sep 2010

Huifeng Bio-Pharmaceutical Technology to acquire Shangqiu Kexin Rutin Processing

Huifeng Bio-Pharmaceutical Technology, Inc., specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives, today announces a definitive agreement under which Huifeng will acquire 90% of the equity ownership of Shangqiu Kexin Rutin Processing Ltd., a local leading Rutin manufacturer in Henan Province, at a price of $1.75 million. As a result of the acquisition, Kexin will be a wholly-owned subsidiary of Huifeng.

9 Sep 2010

Researchers discover first compound to activate enzyme telomerase in human body

Sierra Sciences, in collaboration with TA Sciences, Geron Corporation, PhysioAge, and the Spanish National Cancer Research Center (CNIO), has announced the first compound ever discovered that activates the enzyme telomerase in the human body - a critical prerequisite for technology that could arrest or reverse the aging process in humans.

9 Sep 2010

Seaside reports positive data from STX209 Phase 2 study in ASD

Seaside Therapeutics, Inc. announced today positive data from an open-label Phase 2 study of STX209 conducted in patients with autism spectrum disorders (ASD). The primary endpoint of the study, an improvement on the Irritability subscale of the Aberrant Behavior Checklist (ABC-I), achieved statistical significance (p<0.001).

9 Sep 2010

Major contributing factor to maternal age-associated increase in aneuploidy identified

University of Pennsylvania biologists studying human reproduction have identified what is likely the major contributing factor to the maternal age-associated increase in aneuploidy, the term for an abnormal number of chromosomes during reproductive cell division.

9 Sep 2010

Performance Plus Marketing wins IMA's Circle of Excellence Award for Victoza campaign

In today's troubled economy, keeping a sales force motivated to perform can be critical to the success of a business. That's why Novo Nordisk turned to Performance Plus Marketing (PPM) of Roswell, GA, to build an incentive program to support the launch of its Diabetes medication, Victoza(R). The campaign's unprecedented success resulted in the Incentive Marketing Association's Circle of Excellence Award for Best Sales Incentive Program.

9 Sep 2010

Patheon third-quarter total revenues decrease 0.7% to $163.3 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today its results for the third quarter and nine months ended July 31, 2010. Total revenues for the third quarter were $163.3 million or 0.7% lower than the same period last year. Excluding currency fluctuations, current year third quarter revenues would have increased by approximately 3.9% versus the same period last year.

9 Sep 2010

Liquent reveals new solution branding positioning

Liquent Inc., the global leader in regulatory information management solutions and services, revealed today its new solution branding positioning. The announcement comes approximately three months following the merger of the Liquent and Datafarm organizations announced June 1, 2010.

9 Sep 2010

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc, the global specialty biopharmaceutical company, today announced a joint development and commercialization agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway. This pathway plays critical roles in regulating the growth of skeletal muscle.

9 Sep 2010

Continucare fourth-quarter total revenue increases 5% to $79.3 million

Continucare Corporation today reported strong financial results for its fourth quarter and fiscal year ended June 30, 2010.

9 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

BioMedTracker launches Thought Leader Opinions service for drug information

BioMedTracker, a product of Sagient Research Systems, the leading provider of competitive intelligence and investment analytics on the biotech/pharmaceutical sector, today announced the recent launch of its new service, Thought Leader Opinions (TLO). This service provides its subscribers with direct access to the latest expert opinions in the disease areas that they follow within the intuitive BioMedTracker drug information platform.

9 Sep 2010

Anchor Therapeutics collaborates with OMJPI to develop GPCR targeted therapeutic compounds

Anchor Therapeutics today announced that it has entered into a collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. with the goal of developing G protein coupled receptor (GPCR) targeted therapeutic compounds utilizing Anchor's proprietary pepducin technology.

9 Sep 2010

CombinatoRx is now Zalicus

CombinatoRx, Incorporated today announced that it has changed its name to Zalicus Inc. The company will begin trading under the new ticker symbol ZLCS on the NASDAQ Global Market at market open on September 9, 2010.

9 Sep 2010

First Edition: September 9, 2010

Today's headlines highlight a government study that finds the new health law won't fuel significant increases in spending.

9 Sep 2010

UC San Diego proferssor awarded 2010 Harvey Prize in human health by Technion

Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at the University of California, San Diego School of Medicine has been awarded the 2010 Harvey Prize in human health by the Technion, Israel's premier institute of technology.

9 Sep 2010

ESC recommends InspireMD MGuard mesh technology for thrombotic lesions

InspireMD Ltd., a medical device company engaged in the development and commercialization of the mesh based MGuard(TM) stent systems, is proud to report that mesh-based protection, is now recommended for use in the new Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC). According to the latest European Society of Cardiology Guidelines, published at the ESC Congress last week, "Mesh-based protection may be considered for PCI of highly thrombotic or SVG lesions" - it has received a class IIb recommendation.

9 Sep 2010

Study suggests PTSD symptoms common in Second Generation population

In groups with high rates of posttraumatic stress disorder (PTSD), such as the survivors of the Nazi Death Camps, the adjustment problems of their children, the so called "Second Generation", have received attention by researchers. Studies suggested that some symptoms or personality traits associated with PTSD may be more common in the Second Generation than the general population.

9 Sep 2010

College of Physicians and Surgeons of Ontario releases recommendations to target opioid public health crisis

The College of Physicians and Surgeons of Ontario released a set of wide-ranging recommendations to target the opioid public health crisis. The College is responsible for regulating Ontario's physicians in the public interest.

9 Sep 2010